Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age10-44
SponsorChinese University of Hong Kong

About this trial

This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following:

1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS. 2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI. 3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment. 4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment. 5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI

Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment

Disqualifiers

Women with age <10 or ≥45

Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion

Trial population

The following clients will be included in our study population. * Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI * Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Serum anti-Müllerian hormone (AMH) (pmol/L)

To evaluate the serum AMH level of women who undergo investigation for polycystic ovarian syndrome (PCOS), premature ovarian insufficiency (POI) or subfertility

Time frame
Within 1 to 2 months after the day of recruitment

Secondary outcomes

1

Type of gonadotropin used for ovarian stimulation

To assess the type of gonadotropin used for ovarian stimulation for women undergoing ART treatment

Time frame
From the first 1 day to last 1 day of ovarian stimulation during ART treatment
2

Total gonadotropin dose used for ovarian stimulation

To assess the total gonadotropin dose used for ovarian stimulation for women undergoing ART treatment

Time frame
On the last 1 day of ovarian stimulation during ART treatment
3

Number of oocytes retrieved

To evaluate the number of oocytes retrieved during oocyte retrieval for women undergoing ART treatment

Time frame
On the 1 day of oocyte retrieval during ART treatment
4

Serum follicle stimulation hormone (FSH) (IU/L)

To evaluate the serum FSH level of women who undergo ART treatment

Time frame
On the first 1 day of ovarian stimulation during ART treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.